PH12017502416A1 - 17-hydroxyprogesterone ester-containing oral compositions and related methods - Google Patents

17-hydroxyprogesterone ester-containing oral compositions and related methods

Info

Publication number
PH12017502416A1
PH12017502416A1 PH12017502416A PH12017502416A PH12017502416A1 PH 12017502416 A1 PH12017502416 A1 PH 12017502416A1 PH 12017502416 A PH12017502416 A PH 12017502416A PH 12017502416 A PH12017502416 A PH 12017502416A PH 12017502416 A1 PH12017502416 A1 PH 12017502416A1
Authority
PH
Philippines
Prior art keywords
oral dosage
hydroxyprogesterone
pharmaceutically acceptable
ester
related methods
Prior art date
Application number
PH12017502416A
Other languages
English (en)
Inventor
Mahesh V Patel
Nachiappan Chidambaram
Satish K Nachaegari
Original Assignee
Lipocine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lipocine Inc filed Critical Lipocine Inc
Publication of PH12017502416A1 publication Critical patent/PH12017502416A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Endocrinology (AREA)
  • Physiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
PH12017502416A 2015-06-22 2017-12-22 17-hydroxyprogesterone ester-containing oral compositions and related methods PH12017502416A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562183031P 2015-06-22 2015-06-22
US201662295951P 2016-02-16 2016-02-16
PCT/US2016/038822 WO2016210003A2 (en) 2015-06-22 2016-06-22 17-hydroxyprogesterone ester-containing oral compositions and related methods

Publications (1)

Publication Number Publication Date
PH12017502416A1 true PH12017502416A1 (en) 2018-07-02

Family

ID=57586205

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12017502416A PH12017502416A1 (en) 2015-06-22 2017-12-22 17-hydroxyprogesterone ester-containing oral compositions and related methods

Country Status (12)

Country Link
US (3) US20170035781A1 (enExample)
EP (1) EP3310359B1 (enExample)
JP (1) JP2018522854A (enExample)
CN (1) CN107847506A (enExample)
AU (1) AU2016284459B2 (enExample)
BR (1) BR112017027688A2 (enExample)
ES (1) ES3005883T3 (enExample)
IL (1) IL256493A (enExample)
MX (1) MX2017016823A (enExample)
PH (1) PH12017502416A1 (enExample)
WO (1) WO2016210003A2 (enExample)
ZA (1) ZA201801692B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3050082A1 (en) 2016-04-04 2017-10-12 Omeza LLC Fish oil topical composition
SG11202105551YA (en) * 2018-11-27 2021-06-29 Bayer Ag Process for producing pharmaceutical dosage forms containing task-1 and task-3 channel inhibitors, and the use of same in breathing disorder therapy
CN109662953B (zh) * 2019-02-18 2022-05-10 威海金思力生物科技股份有限公司 一种维生素d软胶囊及其制作方法
US20210121480A1 (en) * 2019-10-23 2021-04-29 Slayback Pharma Llc Stable pharmaceutical compositions containing estradiol and progesterone for oral administration
CN111135153B (zh) * 2020-01-21 2025-08-19 安士制药（中山）有限公司 一种熊去氧胆酸胶囊及其制备方法
CN113616660A (zh) * 2020-05-07 2021-11-09 深圳埃格林医药有限公司 孕激素制剂及其用途
JP2024541958A (ja) * 2020-10-27 2024-11-13 リポシン，インク． カプロン酸ヒドロキシプロゲステロン組成物および早産予防における使用の方法
US11370811B1 (en) 2020-11-20 2022-06-28 Lipocine Inc. (17-)-3-oxoandrost-4-en-17-yl dodecanoate compositions and methods of preparation and use
US11969434B1 (en) 2022-08-29 2024-04-30 Lipocine Inc. Oral allopregnanolone compositions and methods of use
IT202100013898A1 (it) * 2021-05-27 2022-11-27 Hulka S R L Composizione comprendente un estere di alfa-tocoferolo per la riduzione del rischio di parto pretermine
CN116077416B (zh) * 2021-11-05 2024-12-06 深圳埃格林医药有限公司 一种包含孕激素的口服制剂及制备方法和应用
WO2024023173A1 (en) * 2022-07-27 2024-02-01 Ipsico Ug Solid pharmaceutical dosage form comprising a bcs class ii drug and a method for producing the same
US12186327B2 (en) 2022-08-29 2025-01-07 Lipocine Inc. Oral allopregnanolone compositions and methods of use
US20250064897A1 (en) * 2023-08-21 2025-02-27 Cmpd Licensing, Llc Topical administration of glp-1 receptor agonists

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3164520A (en) 1962-10-29 1965-01-05 Olin Mathieson Injectable steroid compositions containing at least 75% benzyl benzoate
NL151903B (nl) 1965-03-24 1977-01-17 Schering Ag Werkwijze ter bereiding van een injectievloeistof door een steroid op te lossen in een mengsel van ricinusolie en benzylbenzoaat.
FR2408345A1 (fr) 1976-11-30 1979-06-08 Besins Jean Louis Nouvelle composition a action anti-conceptionnelle
US4230702A (en) 1978-01-09 1980-10-28 Kali-Chemie Pharma Gmbh Readily enterally absorbable pharmaceutical compositions of per se poorly enterally absorbable pharmacologically active agents
US4439432A (en) 1982-03-22 1984-03-27 Peat Raymond F Treatment of progesterone deficiency and related conditions with a stable composition of progesterone and tocopherols
US5314882A (en) 1984-01-03 1994-05-24 International Foundation For Biochemical Endocrinology Method for promoting growth and improved meat quality in meat producing animals with female steroidal hormones
US5140021A (en) 1986-04-16 1992-08-18 Genesis Systems Corporation Method and dosage form for treatment of premenstrual syndrome
GB8730011D0 (en) 1987-12-23 1988-02-03 Smithkline Dauelsberg Pharmaceutical compositions
WO1990008537A1 (en) 1989-02-06 1990-08-09 Abbott Laboratories Pharmaceutical compositions for oral administration
IT1252867B (it) 1991-12-31 1995-06-28 Gentili Ist Spa Composizioni farmaceutiche contenenti progesterone ad elevata biodisponibilita'
DK95093D0 (da) 1993-08-20 1993-08-20 Novo Nordisk As Farmaceutisk formulering indeholdende et hormon
US5543150A (en) 1993-09-15 1996-08-06 Columbia Laboratories, Inc. Method of progesterone delivery and affect thereof
GB9405304D0 (en) 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
US5633011A (en) 1994-08-04 1997-05-27 Alza Corporation Progesterone replacement therapy
US5948766A (en) 1994-08-23 1999-09-07 Dgf Stoess Ag Use of tasteless, hydrolyzed collagen and agent containing the same
DE19718012C1 (de) 1997-04-29 1998-10-08 Jenapharm Gmbh Verfahren zur Herstellung peroral anwendbarer fester Arzneiformen mit gesteuerter Wirkstoffabgabe
DE19739916C2 (de) 1997-09-11 2001-09-13 Hesch Rolf Dieter Verwendung einer Kombination aus einem Gestagen und einem Estrogen zur kontinuierlichen Ovulationshemmung und ggf. gleichzeitigen Behandlung und/oder Prophylaxe von Tumoren der Brustdrüsen
FR2772617B1 (fr) 1997-12-19 2001-03-09 Besins Iscovesco Lab Comprime de progesterone et son procede de preparation
FR2775599B1 (fr) 1998-03-09 2001-08-17 Besins Iscovesco Lab Composition pharmaceutique a base de progesterone naturelle de synthese et d'oestradiol et son procede de preparation
US6602521B1 (en) 1998-09-29 2003-08-05 Impax Pharmaceuticals, Inc. Multiplex drug delivery system suitable for oral administration
US6214815B1 (en) 1998-12-23 2001-04-10 Ortho-Mcneil Pharmaceuticals, Inc. Triphasic oral contraceptive
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US7374779B2 (en) 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
GB9907715D0 (en) 1999-04-01 1999-05-26 Scherer Corp R P Pharmaceutical compositions
US20030236236A1 (en) 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
US20020131988A1 (en) 1999-12-16 2002-09-19 Foster Todd P. Pharmaceutical implant containing immediate-release and sustained-release components and method of administration
US6544553B1 (en) 1999-12-28 2003-04-08 Watson Pharmaceuticals, Inc. Dosage forms and methods for oral delivery of progesterone
US20040022862A1 (en) 2000-12-22 2004-02-05 Kipp James E. Method for preparing small particles
FR2818905A1 (fr) 2000-12-28 2002-07-05 Cll Pharma Compositions pharmaceutiques colloidales micellaires renfermant un principe actif lipophile
FR2821555B1 (fr) 2001-03-01 2003-05-16 Besins Int Lab Progestatif co-micronise avec un tensioactif, composition pharmaceutique le comprenant, leurs procedes de fabrication et leurs utilisations
FR2832065B1 (fr) 2001-11-13 2004-11-05 Besins Int Belgique Composition pharmaceutique a base de progesterone micronisee son procede de preparation et ses utilisations
JP2005526083A (ja) 2002-03-14 2005-09-02 ワトソン ファーマシューティカルズ， インコーポレイテッド プロゲステロンの経口薬物送達システム
US8216609B2 (en) 2002-08-05 2012-07-10 Torrent Pharmaceuticals Limited Modified release composition of highly soluble drugs
CN1231210C (zh) 2002-08-20 2005-12-14 杭州容立医药科技有限公司 黄体酮胶囊组合物及其制备方法
RS20050184A (sr) 2002-08-28 2007-11-15 Robert Casper Režim zamene estrogena
CN101785775B (zh) 2002-09-05 2015-03-25 潘塔希生物科学股份有限公司 15-或16-位取代的睾酮类似物的药物学应用
JP2004155780A (ja) 2002-10-16 2004-06-03 Taisho Pharmaceut Co Ltd 生活習慣病改善剤組成物
CN101797221B (zh) 2002-12-13 2013-06-12 杜雷科特公司 包含高粘度液体载体材料的口服递药系统
CN1282459C (zh) 2002-12-24 2006-11-01 上海医药工业研究院 黄体酮胶丸及制备方法
US20040266025A1 (en) * 2003-02-06 2004-12-30 Durlin Hickok Screening and treatment methods for prevention of preterm delivery
GB0305941D0 (en) 2003-03-14 2003-04-23 Camurus Ab Composition
CN1299686C (zh) 2003-04-03 2007-02-14 上海医药工业研究院 黄体酮半固体骨架制剂的组合物
CN1623550A (zh) * 2003-12-04 2005-06-08 张伟 己酸羟孕酮口服制剂和用途
CA2548281C (en) 2003-12-09 2013-11-12 Medcrystalforms, Llc Method of preparation of mixed phase co-crystals with active agents
CN1933873A (zh) 2004-03-19 2007-03-21 沃纳奇尔科特公司 延长周期的多相口服避孕方法
GT200500186A (es) 2004-07-07 2006-03-02 Regimenes anticonceptivos con antagonistas del receptor de progesterona y kits
US7473687B2 (en) 2005-03-24 2009-01-06 Emory University Methods for the treatment of a traumatic central nervous system injury
ATE543489T1 (de) 2005-05-26 2012-02-15 Teva Womens Health Inc Orale dosierformen mit progesteron und verwendungs- und herstellungsverfahren dafür
US8828981B2 (en) 2007-02-06 2014-09-09 George Creasy Progesterone for the treatment or prevention of spontaneous preterm birth
ES2731881T3 (es) 2007-09-25 2019-11-19 Formulex Pharma Innovations Ltd Composiciones que comprenden compuestos activos lipófilos y método para su preparación
EP2219554A4 (en) 2007-11-29 2011-05-25 Gregg A Jackson PROGESTER-CONTAINING COMPOSITIONS AND DEVICES
US9011908B2 (en) 2009-04-06 2015-04-21 Banner Life Sciences Llc Progesterone solutions for increased bioavailability
CA2779270A1 (en) 2009-10-29 2011-05-05 The Trustees Of The University Of Pennsylvania Method of predicting risk of preterm birth
WO2011079047A1 (en) 2009-12-23 2011-06-30 Drugtech Corporation Methods for reducing the occurrence of preterm delivery and other pregnancy-related conditions
US20110262502A1 (en) * 2010-02-08 2011-10-27 Prairie Pharmaceuticals LLC Pulmonary delivery of 17-hydroxyprogesterone caproate (17-hpc)
CA2789238C (en) 2010-03-09 2020-05-12 Dignity Health Methods for inhibiting preterm labor and uterine contractility disorders and preventing cervical ripening
US9375437B2 (en) 2010-06-18 2016-06-28 Lipocine Inc. Progesterone containing oral dosage forms and kits
US20110312928A1 (en) 2010-06-18 2011-12-22 Lipocine Inc. Progesterone Containing Oral Dosage Forms and Related Methods
US20110312927A1 (en) 2010-06-18 2011-12-22 Satish Kumar Nachaegari Progesterone Containing Oral Dosage Forms and Related Methods
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
US8951996B2 (en) * 2011-07-28 2015-02-10 Lipocine Inc. 17-hydroxyprogesterone ester-containing oral compositions and related methods

Also Published As

Publication number Publication date
EP3310359A4 (en) 2019-04-03
WO2016210003A2 (en) 2016-12-29
ZA201801692B (en) 2019-09-25
MX2017016823A (es) 2018-03-12
EP3310359B1 (en) 2024-12-18
AU2016284459B2 (en) 2021-12-23
NZ739324A (en) 2024-05-31
IL256493A (en) 2018-02-28
CN107847506A (zh) 2018-03-27
AU2016284459A1 (en) 2018-02-15
US20210169900A1 (en) 2021-06-10
BR112017027688A2 (pt) 2018-09-04
JP2018522854A (ja) 2018-08-16
US11590147B2 (en) 2023-02-28
US20190275060A1 (en) 2019-09-12
US20170035781A1 (en) 2017-02-09
WO2016210003A3 (en) 2017-02-09
ES3005883T3 (en) 2025-03-17
EP3310359A2 (en) 2018-04-25

Similar Documents

Publication Publication Date Title
PH12017502416A1 (en) 17-hydroxyprogesterone ester-containing oral compositions and related methods
MX385798B (es) Composiciones orales que contienen un ester de 17-hidroxiprogesterona y metodos relacionados.
WO2012079092A3 (en) Testosterone undecanoate compositions
CY1124052T1 (el) Δισκιο διασπειρομενο στο στομα περιεχον οιστετρολη
WO2013022783A3 (en) Progesterone containing oral dosage forms and related methods
CL2019000209A1 (es) Formulación novedosa administrable por la vía oral.
WO2011160136A3 (en) Progesterone containing oral dosage forms and related methods
MY207496A (en) Sustained-release formulations of colchicine and methods of using same
MX2020005942A (es) Delgada pelicula oral con alta carga de agente activo.
PE20142314A1 (es) Composiciones intranasales de dexmedetomidina y metodos de uso de ellas
EA201291410A1 (ru) Фармацевтические композиции, содержащие 4-амино-5-фтор-3-[6-(4-метилпиперазин-1-ил)-1h-бензимидазол-2-ил]-1h-хинолин-2-она лактат моногидрат
CL2016001424A1 (es) Composiciones de liberación retardada de lionaclotida
RU2011152105A (ru) Составы таблеток 3-цианохинолина и их применение
NZ620879A (en) A novel formulation of indomethacin
PH12017502325B1 (en) Orodispersible dosage unit containing an estetrol component
PH12013500173A1 (en) Oral controlled release pharmaceutical compositions of blonanserin
EP2493312A4 (en) Solid pharmaceutical compositions containing an integrase inhibitor
FI3313408T3 (fi) Drospirenonipohjainen ehkäisyvalmiste ylipainoiselle naispotilaalle
RU2014142066A (ru) Состав с длительным высвобождением для снижения частоты мочеиспускания и способ его применения
PH12019500154A1 (en) Formulation having improved ph-dependent drug-release characteristics, containing esomeprazole or pharmaceutically acceptable salt thereof
RU2016115985A (ru) Лактоферрин для лечения ibd, вызванного бактериальной инвазией
IN2014MN02156A (enExample)
WO2016091805A3 (de) Naloxon-monopräparat und mehrschichttablette
MX2015010594A (es) Esteres de testosterona de cadena larga lipobalanceados para suministro oral.
RU2016136666A (ru) Составы на основе прогестерона